Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 924.2× sales vs its 480.6× historical median P/S.
Fair value ≈ $171.52 · price $329.83 today
Overvalued · 92% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$RVPH Based on industry patterns, Reviva’s profile, and market dynamics, the likelihood of a buyout or M&A (merger/acquisition) is moderate to high (50-70%) within 12-18 months of NDA submission approval. This estimate draws from
• Historical Precedents in Schizophrenia Biotechs: Late-stage assets in this space often attract acquirers due to high unmet need and blockbuster potential (e.g., peak sales forecasts for brilaroxazine: $500M-$1B+ annually)
• Karuna Therapeutics ($KRTX) filed an NDA for KarXT (similar novel antipsychotic) in 2023; Bristol Myers Squibb (BMS) acquired it for $14B in 2024, just months post-filing, valuing the asset at ~5-7x projected peak sales
• Cerevel Therapeutics ($CERE) advanced emraclidine (Phase 3-ready muscarinic agonist); AbbVie bought it for $8.7B in 2024 amid NDA preparations.
• These deals highlight Big Pharma’s (BMS, AbbVie, Pfizer) appetite for differentiated schizophrenia candidates to refill pipelines amid patent cliffs (Eliquis, Keytruda)
@Covode13 @PDM21 @Rony4AM @richardnj58 @mmtiddy “No upside proves the point”? Not in small-cap biotech. Most real winners looked dead before they ran. Examples:
• $KRTX sat under $6 with zero interest → Phase 2 readout → $200+ buyout.
• $SRPT traded at $3 for years, called a scam → data hit → $150+.
• $IMVT was left for dead under $5 → Phase 2 success → $40+.
• $NVCT flat at $1–2 forever → FDA breakthrough designation → 10×.
• $APLS was ignored under $4 → Phase 3 approval → $80.
Flat price ≠ no value. It’s how small biotechs behave before catalysts.
Cardiol now has Phase 3 underway, strong myocarditis MRI data coming, runway to 2027, zero debt, Orphan status in two indications, and a 13-year Eli Lilly CMO running development.
This setup is exactly what those small-cap winners looked like right before they rerated hard.
MapLight Therapeutics' ( $MPLT ) IPO is Reportedly Well Oversubscribed, Ahead of its Scheduled Pricing on October 26 - Yesterday, As Per Bloomberg/BBG.
$KRTX - $BMY
https://www.sec.gov/Archives/edgar/data/1770069/000119312525231829/d90027ds1a.htm
The current offering is 14.75 million shares at $17 each to raise $250.8 million. The company is expected to stop taking orders Thursday after markets close in New York; the offering is scheduled to price on October 26, according to a management presentation.
Morgan Stanley, Jefferies Financial Group Inc., Leerink Partners, and Stifel Financial Corp. are working on the offering.
MapLight is pioneering the discovery, development, and delivery of transformative treatments for brain disorders:
$RVPH
Catalysts Driving Squeeze Risk
Upcoming events could ignite covering:
November 6-7, 2025: Open-Label Extension (OLE) data presentation for brilaroxazine (schizophrenia drug).
November 11-12, 2025: BIO CEO & Investor Conference for visibility.
November 17, 2025: Q3 earnings report.
December 9, 2025: Neuro Innovation Forum discussing clinical programs.
Q4 2025 / Early Q1 2026: Phase 3 interim data readout for brilaroxazine, a major value driver.
Recent: $9 million offering (September 2025) and OLE trial completion boosted a 21% surge, with positive data showing efficacy and biomarker improvements.
Positive outcomes (e.g., robust efficacy, low discontinuation) could mirror peers like $DRUG or $ALGS, triggering parabolic moves. Buyout chatter adds upside, given $83 million cap vs. acquisitions like $KRTX ($14B).
$TSLA Folks please focus on $KRTX to fix your Elon derangement syndrome. Also invest in psychological treatment drug companies because the mental illness is stacking up.
@sporalysis @stocky1234 I take back that I've never used them. I did place an upside order once - on $KRTX - and missed out BIG time when it exploded and never came back!
$KRTX Karuna Therapeutics, Inc. (NASDAQ:KRTX) A Promising Biopharmaceutical Company Advancing Transformative Therapies https://beyondspx.com/article/karuna-therapeutics-inc-nasdaq-krtx-a-promising-biopharmaceutical-company-advancing-transformative-therapies
$RVPH
https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Presents-New-Pooled-Interim-Long-Term-Safety-and-Metabolic-Outcomes-Data-from-the-EMERGENT-Program-Evaluating-KarXT-in-Schizophrenia-at-the-2024-Annual-Congress-of-the-Schizophrenia-International-Research-Society/default.aspx
15% drop out due to adverse events of $krtx / $bmy drug
$RVpH drop out about 1/10 of that
@ThisIsBiotech I agree about possible impacts, but both are one year studies. Both are targeting a critical unmet need.
$krtx / $bmy highlight weight loss.
Curious to see what your DD shows.
